Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
Pfizer Inc. won’t escape a large antitrust case alleging it conspired with Teva Pharmaceuticals USA Inc. to stifle competition for blockbuster psychiatric drug Effexor XR.
The U.S. Supreme Court Feb. 20 denied a petition by Wyeth LLC (now part of Pfizer) to review an appellate decision that revived monopolization claims by Effexor buyers, including large buyers like Rite Aid Corp. The case now returns to the U.S. District Court for the District of New Jersey for discovery.
The dispute involves what types of non-cash payments between two drug companies are evidence of illegal agreements to divide a drug market. Plaintiffs say Wyeth agreed with Teva not to launch an authorized generic of its own to compete with Teva’s version.
Wyeth, the owner of the Effexor patent, contended that it gave Teva an exclusive license, which should be shielded from consideration as an illegal “pay for delay” bargain because granting a license is a core patent right.
The question of what constitutes a “payment” from the patent holder to a generic drugmaker to delay its entry into the market is important in many pay-for-delay cases. Drug companies rarely exchange cash in patent agreements after the Supreme Court’s 2013 FTC v. Actavis decision said big cash payments can lead to antitrust lawsuits. Courts are now wrestling with which other promises and exchanges of value trigger antitrust law.
Rutgers Law Professor Michael Carrier told Bloomberg Law that the Supreme Court’s decision not to hear the case is “unsurprising and completely appropriate.”
“As courts have recognized after Actavis, the payment by which a brand company can keep a generic off the market can take many forms,” Carrier said.
Carrier, who led a group of professors in a brief supporting the plaintiffs in the Third Circuit, said that court’s decision “will play an important role going forward.”
The U.S. Court of Appeals for the Third Circuit reversed the district court’s decision that the plaintiffs didn’t present a reliable estimate of the non-cash payment’s cash value. The Third Circuit opinion, which now stands unchallenged, said the district court’s standard was too high a hurdle for plaintiffs who haven’t had a chance to collect evidence about their claims through discovery. The circuit court said the plaintiffs plausibly alleged that Wyeth made a large, unexplained payment to Teva as a matter of law.
The case has been pending since May 2011. The defendants answered the plaintiffs claims in the district court last week.
The case: Wyeth LLC v. Rite Aid Corp. , U.S., No. 17-771, cert. denied 2/20/18 .
To contact the reporter on this story: Eleanor Tyler in Washington at email@example.com
To contact the editor responsible for this story: Fawn Johnson at firstname.lastname@example.org
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)